Farydak-rems.com

Farydak-rems.com has Server used 72.10.49.6 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2014-12-11 (4 years, 313 days) and hosted in Culver City United States, server ping response time 29 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Farydak-rems keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Farydak rems program
2 Farydak rems
3 Farydak rems enrollment

Hosting Provider

Website: Farydak-rems.com
Hostname: securabio.com
Country:
Region: CA
City: Culver City
Postal Code: 90232
Latitude: 34.020198822021
Longitude: -118.39279937744
Area Code: 310
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   Butovo.com (8 seconds ago)

   Authorsloanj.com (19 seconds ago)

   X3dna.org (6 seconds ago)

   Streamen.com (19 seconds ago)

   Burnhaminjurylaw.com (12 seconds ago)

   Farydak-rems.com (0 seconds ago)

   P-bot.com (13 seconds ago)

   Truyentranh.com (10 seconds ago)

   Rivercityreunion.com (9 seconds ago)

   Plazapub.com (19 seconds ago)

   Whiskyinternationalonline.com (11 seconds ago)

   Medicalhair4u.com (16 seconds ago)

   Wsnm.org (8 seconds ago)

   Michaelsfencecompany.com (10 seconds ago)

   Cmmtechnology.com (41 seconds ago)

   Joebuschmann.com (12 seconds ago)

   Q106fm.com (12 seconds ago)

   Warsoftheroses.org (5 seconds ago)

   Theweddingboutique.net (44 seconds ago)

   Mpeblog.com (37 seconds ago)

Results For Websites Listing

Found 56 Websites with content related to this domain, It is result after search with search engine

FARYDAK REMS

What is the FARYDAK REMS? A REMS (Risk Evaluation and Mitigation Strategy) is a program required by the FDA to manage known or potential serious risks associated with a drug product. The FDA has determined that a REMS is necessary to ensure that the benefits of FARYDAK ® (panobinostat) outweigh the risks.

https://farydak-rems.com/

FDA-REQUIRED REMS* SAFETY INFORMATION - farydak-rems.com

part of the FARYDAK REMS program. Indication How can I minimize this risk? • Patient selection and evaluation o Do not start FARYDAK if patient has • Recent myocardial infarction • Unstable angina • QTcF >450 msec • Clinically significant ST-segment or T-wave abnormalities • Monitor ECG o Perform an ECG prior to start of therapy and

https://farydak-rems.com/globalassets/products71.com/farydak-rems/forvalidationfdk-1178344remsfactsheet.pdf

Approved Risk Evaluation and Mitigation Strategies (REMS)

The goal of the FARYDAK REMS is to mitigate the risks of severe diarrhea and cardiac toxicities (severe and fatal cardiac ischemic events, severe arrhythmias, and ECG changes) associated with FARYDAK treatment. by informing healthcare providers about the risks of severe diarrhea and cardiac toxicities associated with FARYDAK.

https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=344

I. Goal(s) II. REMS elements

FARYDAK REMS materials will be prominently displayed and disseminated at relevant scientific meetings where Novartis has a presence (e.g., booth) for the duration of the REMS. 5.

https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM435548.pdf

FDA-REQUIRED REMS* SAFETY INFORMATION

FDA-REQUIRED REMS* SAFETY INFORMATION Boxed Warning: Severe Diarrhea and Cardiac Toxicities with FARYDAK Treatment ©2015 Novartis 2/15 *A REMS (Risk Evaluation and Mitigation Strategy) is a program required by the FDA to manage known or potential serious risks associated with a drug product. www.FARYDAK-REMS.com for more information.

http://www.pdr.net/labels/Communications/1000207/820938_814958_FAK_LV17_REMS_letter_HCP.pdf

Novartis receives FDA approval of Farydak - multivu.com

Novartis receives FDA approval of Farydak ®, the first HDAC inhibitor for patients with multiple myeloma. Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD 1; Farydak prolonged median PFS benefit when used with bortezomib and dexamethasone combination versus combination alone (from 6

http://www.multivu.com/players/English/7424351-novartis-farydak-fda-approval/

Recently Analyzed Sites